All Updates

All Updates

icon
Filter
Funding
Antiverse raises GBP 2.5 million; identifies eight therapeutic antibodies
AI Drug Discovery
Mar 2, 2023
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Mar 2, 2023

Antiverse raises GBP 2.5 million; identifies eight therapeutic antibodies

Funding

  • UK-based AI biotechnology company, Antiverse, has raised GBP 2.5 million (USD 3 million) from various investors, including InnoSpark, AngelHub, and Tensor Ventures. The round brings the company’s total funds raised to date to GBP 4.3 million (USD 5.2 million). 

  • The proceeds were earmarked for the in-house development of antibodies that show high-affinity blocking function; i.e the ability to tightly and specifically bind to a target molecule, preventing its normal function and interfering with its interactions with other molecules.

  • Simultaneously, the company announced the discovery of eight therapeutic antibodies using its proprietary AI-powered platform. The antibodies will target two G-protein-coupled receptors (GPCRs), of which seven have been characterized and will be developed in-house.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.